Kezar Life Sciences GAAP EPS of -$0.25

Nov. 10, 2022 5:14 PM ETKezar Life Sciences, Inc. (KZR)By: Urvi Shah, SA News Editor
  • Kezar Life Sciences press release (NASDAQ:KZR): Q3 GAAP EPS of -$0.25.
  • Cash, cash equivalents and marketable securities totaled $290.4 million as of September 30, 2022, compared to $208.4 million as of December 31, 2021.
  • Total shares of common stock outstanding were 68.4 million shares as of September 30, 2022.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.